Clinical grade stem cells to be manufactured by Stemedica as it awaits FDA approval of an IND to commence clinical trials

August 21, 2009

Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (“FDA”) to discuss a proposed IND to use Stemedica’s proprietary line of allogeneic mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke. (Medical News)